Reading this on a mobile device? Try our optimized mobile version here:

November 7, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Complimentary Webinar - Simplifying the Audit Management Process
Tuesday, November 27, 2012, 11:00 am Eastern
Join us to hear how the new TrackWise Audit Execution Package Bundle drives efficiency through enhanced TrackWise capabilities, advanced services and training. Learn how the TrackWise Audit Execution Package can improve productivity, reduce costs and streamline your audit processes in the most effective manner. Register Now!
  Health Care & Policy 
  • Pfizer's arthritis drug Xeljanz wins FDA approval
    The FDA approved Pfizer's Xeljanz, or tofacitinib, to treat patients with moderate to severe rheumatoid arthritis who can't tolerate methotrexate or for whom it is ineffective. The approval makes Xeljanz the first rheumatoid arthritis drug from a new class of pain treatments known as JAK inhibitors. Yahoo/The Associated Press (11/6) LinkedInFacebookTwitterEmail this Story
  • Novartis' heart failure drug serelaxin cuts mortality in trial
    Novartis' experimental drug serelaxin was associated with a 37% reduction in deaths from any cause in hospitalized patients with acute heart failure compared with placebo during a late-stage trial. The drug, a form of human hormone, also reduced episodes of worsening heart failure symptoms by more than 45% and cut hospital stays by nearly a day. Novartis plans to submit the drug for approval. Reuters (11/7) LinkedInFacebookTwitterEmail this Story
  • LinkedIn brings the biotech world down to size
    The work and social platform LinkedIn operates somewhat like an ongoing life sciences industry conference, allowing investors to connect with researchers and consultants, writes Luke Timmerman. Mark Levin, a founding partner at Third Rock Ventures, uses the platform to connect with potential partners and consultants. "Biotech is a geographically far-flung industry, with hundreds of companies and vendors, who all need to work together in trusting relationships to keep the whole enterprise afloat," Timmerman writes. Xconomy (11/5) LinkedInFacebookTwitterEmail this Story
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Company & Financial News 
  • Takeda buys U.S. drugmaker for $140M
    Takeda America Holdings agreed to pay $140 million to purchase Envoy Therapeutics, a privately held drug discovery firm. The acquisition will give Takeda access to Envoy's pipeline of preclinical central nervous system drugs as well as its proprietary bacTRAP technology, which Takeda says combines "innovative genetic engineering with molecular biology techniques for labeling and extracting the protein-making components of specific types of cells." Genetic Engineering & Biotechnology News (11/6), PharmaTimes (U.K.) (11/6) LinkedInFacebookTwitterEmail this Story
  • U.K. groups to develop iPS cell database
    The U.K.'s Medical Research Council and the Wellcome Trust will put $20.5 million toward the development of a database of induced pluripotent stem cells, to be called the Human Induced Pluripotent Stem Cell Initiative. The initiative will aim to produce iPS cells from healthy volunteers and from patient groups for use in genetic disease studies. The database will function as a "comprehensive resource for investigating how genetic variation impacts on cell behavior and how diseases linked to a specific genetic defect can result in a broad spectrum of clinical abnormalities," according to the Wellcome Trust. GenomeWeb Daily News (free registration) (11/6) LinkedInFacebookTwitterEmail this Story

With in-depth industry knowledge, GE Capital, Healthcare Financial Services' dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Stop just banking. And start building. Click here to find out more.
  Industrial & Environmental 
  • Sapphire Energy, research group team up for algae-based fuel
    Sapphire Energy has joined forces with nonprofit research group Institute for Systems Biology to further development of algae-based fuels. "By working with ISB to apply their systems biology approach, we're able to more rapidly identify genes and regulatory pathways that can increase yield and move us toward our goal of making green crude a market-viable crude oil alternative," said Alex Aravanis, chief science officer of Sapphire Energy. (11/2) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Success is often just an idea away."
--Frank Tyger,
American cartoonist, columnist and humorist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information